Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

This study has been completed.
Information provided by (Responsible Party):
Biodel Identifier:
First received: April 13, 2010
Last updated: July 30, 2015
Last verified: July 2015
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.

Condition Intervention Phase
Type 1 Diabetes Mellitus
Drug: Viaject 7
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Resource links provided by NLM:

Further study details as provided by Biodel:

Primary Outcome Measures:
  • 3 hour incremental area under the glucose curve after a standardized high glycemic index meal. [ Time Frame: 3 hours ]

Secondary Outcome Measures:
  • Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe). [ Time Frame: 72 hours ]

Enrollment: 20
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Formulation A
Single Injection
Drug: Viaject 7
100IU/mL administered subcutaneously
Experimental: Formulation B
Single Injection
100IU/mL administered subcutaneously


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females diagnosed with type 1 diabetes mellitus for at least 6 months
  2. Current usage of subcutaneous insulin pump treatment with one of the following pumps:

    • Medtronic Paradigm®
    • Animas®
    • OmniPod®
    • ACCU-CHEK Spirit®
  3. Age 18-75 years
  4. HbA1c of 6.0 - 9.0% at screening visit.
  5. Willingness to attend 9 clinic visits.

Exclusion Criteria:

  1. Pregnancy or Lactation
  2. Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).
  3. Anemia
  4. Congestive heart failure.
  5. Visual impairment preventing reading of glucose meter values or the ability to use an insulin pump or continuous glucose monitoring device.
  6. Active coronary artery disease or heart procedure within the past 4 months.
  7. Active foot ulceration.
  8. Severe peripheral arterial disease.
  9. Stroke within the past 6 months.
  10. Active alcohol abuse, substance abuse, or severe mental illness.
  11. Active cancer, except basal cell or squamous cell skin cancers.
  12. Major surgical operation within 30 days prior to screening.
  13. Seizure disorder (epilepsy).
  14. Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.
  15. Currently use of corticosteroids.
  16. History of major non-compliance.
  17. Use of an investigational drug within 30 days prior to screening.
  18. Bleeding disorder, treatment with warfarin, or low platelet count.
  19. Any insulin allergy
  20. Current complaints of major infusion site problems with commercially- available insulin preparations, such as frequent occurrence of infections, marked swelling or marked erythema.
  21. History of gastroparesis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01110746

United States, Oregon
Oregon Health and Science University/Legacy Health System
Portland, Oregon, United States, 97232
Sponsors and Collaborators
  More Information

Responsible Party: Biodel Identifier: NCT01110746     History of Changes
Other Study ID Numbers: VIAject -032J
Study First Received: April 13, 2010
Last Updated: July 30, 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Lispro
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 25, 2017